Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada
- PMID: 24319083
- PMCID: PMC3922214
- DOI: 10.1093/cid/cit796
Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada
Abstract
Background: Preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine (Truvada) has demonstrated efficacy in placebo-controlled clinical trials involving men who have sex with men, high-risk heterosexuals, serodiscordant couples, and intravenous drug users. To assist in the real-world provision of PrEP, the Centers for Disease Control and Prevention (CDC) has released guidance documents for PrEP use.
Methods: Adult infectious disease physicians were surveyed about their opinions and current practices of PrEP through the Emerging Infections Network (EIN). Geographic information systems analysis was used to map out provider responses across the United States.
Results: Of 1175 EIN members across the country, 573 (48.8%) responded to the survey. A majority of clinicians supported PrEP but only 9% had actually provided it. Despite CDC guidance, PrEP practices were variable and clinicians reported many barriers to its real-world provision.
Conclusions: The majority of adult infectious disease physicians across the United States and Canada support PrEP but have vast differences of opinion and practice, despite the existence of CDC guidance documents. The success of real-world PrEP will likely require multifaceted programs addressing barriers to its provision and will be assisted with the development of comprehensive guidelines for real-world PrEP.
Keywords: HIV; PrEP; providers; survey.
Figures


Comment in
-
Reply to Sachdev et al.Clin Infect Dis. 2014 Jun;58(12):1788. doi: 10.1093/cid/ciu231. Epub 2014 Apr 12. Clin Infect Dis. 2014. PMID: 24729555 Free PMC article. No abstract available.
-
Intentions to prescribe preexposure prophylaxis are associated with self-efficacy and normative beliefs.Clin Infect Dis. 2014 Jun;58(12):1786-7. doi: 10.1093/cid/ciu229. Epub 2014 Apr 12. Clin Infect Dis. 2014. PMID: 24729556 Free PMC article. No abstract available.
References
-
- Fowler MG, Gable AR, Lampe MA, Etima M, Owor M. Perinatal HIV and its prevention: progress toward an HIV-free generation. Clin Perinatol. 2010;37:699–719. vii. - PubMed
-
- Kwon JA, Anderson J, Kerr CC, et al. Estimating the cost-effectiveness of needle-syringe programs in Australia. AIDS. 2012;26:2201–10. - PubMed
-
- Lindegren ML, Byers RH, Jr, Thomas P, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA. 1999;282:531–8. - PubMed
-
- Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41:777–813. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous